NCT06046196View on ClinicalTrials.gov

Clinical Trial to Evaluate the Efficacy and Safety of Sarpogrelate SR in Patients With Chronic Artery Occlusive Disease

PHASE4CompletedINTERVENTIONAL
Enrollment

148

Participants

Timeline

Start Date

November 18, 2020

Primary Completion Date

March 9, 2023

Study Completion Date

March 9, 2023

Conditions
Arterial Occlusive DiseasesIntermittent Claudication
Interventions
DRUG

Sarpogrelate SR

Sarpogrelate SR 300mg, once a daily, for 24weeks

DRUG

Sarpogrelate

Sarpogrelate 100mg, 3 times a day, for 24weeks

Trial Locations (7)

10380

Inje University Ilsan Paik Hospital, Goyang-si

25440

GangNeung Asan Hospital, Gangneung-si

44602

Ulsan University Hospital, Ulsan

49201

Dong-A University Hospital, Busan

02841

Korea University ANAM Hospital, Seoul

05505

Asan Medical Center, Seoul

06591

The Catholic University of Korea, Seoul ST. Mary's Hospital, Seoul

All Listed Sponsors
lead

Yuhan Corporation

INDUSTRY

NCT06046196 - Clinical Trial to Evaluate the Efficacy and Safety of Sarpogrelate SR in Patients With Chronic Artery Occlusive Disease | Biotech Hunter | Biotech Hunter